Episode
Markus Warmuth: Eliminating Pathogenic Proteins with Molecular Glue Degraders
- Podcast
- Behind the Breakthroughs
- Published
- Mar 11, 2026
- Duration seconds
- 2903
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/behind-the-breakthroughs-7055075/episodes/markus-warmuth-eliminating-pathogenic-proteins-with-molecular-glue-degraders/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/behind-the-breakthroughs-7055075/markus-warmuth-eliminating-pathogenic-proteins-with-molecular-glue-degraders.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Traditional drugs usually inhibit specific protein sites, but many disease-causing proteins lack accessible or unique motifs, leaving them “undruggable.” Targeted Small-molecule drugs have long been the quiet workhorses of modern medicine, slipping inside cells to target disease-driving proteins, even as biologics, immunotherapies, and genetic medicines have taken center stage in recent years. Yet thousands of disease-related proteins remain “undruggable” because they lack the structural pockets needed for traditional inhibitors to bind. In this episode, Markus Warmuth, MD, CEO of Monte Rosa Therapeutics, explains how molecular glue degraders harness the cell’s protein-disposal machinery to eliminate harmful proteins entirely, and how the company’s QUEEN discovery platform is advancing new therapies in cancer and autoimmune disease. Produced and hosted by Jonathan D. Grinstein, PhD Audio mixed and mastered by Erick Ziegler Brought to you by Inside Precision Medicine (SAGE Publishing) Hosted on Acast. See acast.com/privacy for more information.